塞利尼索联合R-CHOP方案治疗弥漫大B细胞淋巴瘤的临床疗效  

The Clinical Efficacy of Selinexor Combined with R-CHOP Regimen in the Treatment of Diffuse Large B-Cell Lymphoma

作　　者：周颖 蒋磊 王银花 许倩 ZHOU Ying;JIANG Lei;WANG Yinhua;XU Qian(Department of Hematology(Ward 42),Suzhou Ninth People's Hospital,Suzhou,Jiangsu,215200,China)

机构地区：[1]苏州市第九人民医院血液科(42病区),江苏苏州215200

出　　处：《中外医疗》2025年第6期5-9,共5页China & Foreign Medical Treatment

基　　金：2023年院级科研启动基金项目(YK202321)。

摘　　要：目的探讨塞利尼索联合利妥昔单抗-环磷酰胺-多柔比星-长春新碱-泼尼松方案(rituximabcyclophosphamide-doxorubicin-vincristine-prednisone,R-CHOP)方案治疗弥漫大B细胞淋巴瘤(diffuse large Bcell lymphoma,DLBCL)的疗效及安全性。方法回顾性选取2020年1月—2023年4月苏州市第九人民医院收治的64例DLBCL患者临床资料。依据治疗方案的不同进行分组,各32例。将采用R-CHOP方案治疗的患者纳入单用组,采用塞利尼索联合R-CHOP方案治疗的患者纳入联合组。比较两组治疗的临床疗效、血液指标[血清糖类抗原125(carbohydrate antigen 125,CA125)、血管内皮生长因子(vascular endothelial growth fac⁃tor,VEGF)、乳酸脱氢酶(lactate dehydrogenase,LDH)]、欧洲癌症研究与治疗组织生命质量核心问卷(Euro⁃pean Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30,QLQ-C30)评分、不良反应发生情况。结果联合组患者治疗总有效率为87.50%(28/32),高于单用组的65.63%(21/32),差异有统计学意义(χ^(2)=4.267,P<0.05)。治疗后,两组的血液指标CA125、VEGF、LDH水平均较治疗前降低,且联合组各血液指标水平均低于单用组,差异均有统计学意义(P均<0.05)。治疗后,两组患者的QLQ-C30量表各维度评分均较治疗前升高,其中联合组的躯体功能、情绪功能评分均高于单用组,差异均有统计学意义(P均<0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论塞利尼索联合R-CHOP方案能提高DLBCL患者的临床疗效,改善血液指标和生命质量,未增加药物使用不良反应,安全性好。Objective To explore the efficacy and safety of selinexor combined with the rituximab-cyclophosphamidedoxorubicin-vincristine-prednisone(R-CHOP)in the treatment of diffuse large B-cell lymphoma(DLBCL).Methods The clinical data of 64 DLBCL patients admitted to the Suzhou Ninth People's Hospital from January 2020 to April 2023 were retrospectively selected.The patients were grouped according to different treatment regimens,with 32 cases in each group.The patients treated with the R-CHOP regimen were included in the single-treatment group,and those treated with the combination of selinexor and the R-CHOP regimen were included in the combination group.The clinical efficacy,blood indices[serum carbohydrate antigen 125(CA125),vascular endothelial growth factor(VEGF),lactate dehydrogenase(LDH)],scores of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30(QLQ-C30),and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the combination group was 87.50%(28/32),which was higher than 65.63%(21/32)in the single-treatment group,and the difference was statistically significant(χ^(2)=4.267,P<0.05).After treatment,the levels of blood indices CA125,VEGF,and LDH in both groups were lower than those before treatment,and the levels of each blood index in the combination group were lower than those in the single-treatment group,and the differences were statistically significant(all P<0.05).After treatment,the scores of each dimension of the QLQ-C30 scale in both groups were higher than those before treatment,among them,the scores of physical function and emotional function in the combination group were higher than those in the single-treatment group,and the differences were statistically significant(all P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the single-treatment group and the combination group(P>0.05).Conclusion The combination of selinexor and t

关 键 词：塞利尼索 联合化疗 弥漫大B细胞淋巴瘤 疗效 安全性 

分 类 号：R733[医药卫生—肿瘤]